RayzeBio Inc

RYZB

$

Closing

1D

YTD

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$

Analysts' Rating

BUY

Price Target (Mean)

31.33333

Total Analysts

4

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The Company is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The Company’s drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The Company is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.